683 Capital Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

683 Capital Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$70K	–	374
2021 Q4	$70K	Buy	+200,000	New	+$79.5K	﹤0.01%	311
2021 Q3	–	Sell	-200,000	Closed	-$102K	–	224
2021 Q2	$102K	Buy	+200,000	New	+$90K	﹤0.01%	190
2020 Q4	–	Sell	-200,000	Closed	-$102K	–	214
2020 Q3	$102K	Hold	200,000	–	–	0.01%	134
2020 Q2	$94K	Hold	200,000	–	–	0.01%	134
2020 Q1	$18K	Hold	200,000	–	–	﹤0.01%	140
2019 Q4	$36K	Hold	200,000	–	–	﹤0.01%	161
2019 Q3	$40K	Hold	200,000	–	–	﹤0.01%	141
2019 Q2	$45K	Hold	200,000	–	–	﹤0.01%	153
2019 Q1	$32K	Hold	200,000	–	–	﹤0.01%	159
2018 Q4	$66K	Buy	+200,000	New	+$64.2K	﹤0.01%	162

Other funds holding RVPHW

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

683 Capital Management's RVPHW Position: Q1 2022 in Review

683 Capital Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q1 2022, closing a stake of 200,000 shares — an estimated $70K sold.

683 Capital Management first reported a position in RVPHW in Q4 2018 and held it in 10 quarters. The position peaked at $102K in Q2 2021. 5 funds tracked by Wall St. Rank hold RVPHW as of Q1 2022.

683 Capital Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q1 2022 after selling out during the quarter.
683 Capital Management sold 200,000 Reviva Pharmaceuticals Warrants shares in Q1 2022, an estimated $70K.
683 Capital Management first reported a position in Reviva Pharmaceuticals Warrants in Q4 2018 and held it in 10 quarters.
683 Capital Management's Reviva Pharmaceuticals Warrants position peaked at $102K in Q2 2021.
5 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q1 2022.

Based on 683 Capital Management's 13F filing for Q1 2022, filed 16 May 2022.